微波消融序贯^(131)I-chTNT放射免疫法治疗肺癌的疗效及其对患者生存质量的影响  

Efficacy of microwave ablation combined with ^(131)I-chTNT radioimmunotherapy in treatment of lung cancer and its effect on life quality of patients

作　　者：赵子粼[1] 黄梁艳[1] 罗敏[1] 王红治[1] 廖秀杰[1] 

机构地区：[1]中国人民解放军第三○三医院,南宁530021

出　　处：《山东医药》2013年第43期9-11,共3页Shandong Medical Journal

基　　金：国家卫生部医药科技发展研究中心资助项目(W2009BX044)

摘　　要：目的探讨微波消融序贯131I-肿瘤细胞核人鼠嵌合单克隆抗体(131I-chTNT)放射免疫法治疗非小细胞肺癌的疗效及其对患者生存质量的影响。方法将61例非小细胞肺癌患者随机分为两组,A组(32例)为外科手术治疗后放化疗,B组(29例)为微波消融联合131I-chTNT放射免疫治疗后化疗。对两组患者进行临床疗效比较和生存质量评定。结果治疗后6个月,A组局部病灶控制率为84.4%,B组为89.7%,两组相比,P<0.05;两组不良反应发生率相近(P>0.05)。治疗后6个月,两组患者生存质量评分均优于治疗前,其中B组的认知、情绪、社会功能量表及疼痛、呼吸困难症状量表评分结果与A组相比,P均<0.05。结论微波消融序贯131I-chTNT放射免疫法治疗肺癌安全、有效,能明显提高肺癌患者生存质量。Objective To investigate the efficacy of sequential iodine-131-labeled tumor cell nucleus chimeric monoclonal antibody （^131I-chTNT） radioimmunotherapy combined with microwave ablation in treatment of non-small-cell lung cancer （NSCLC） and its effect on quality of life in patients.Methods A total of 61 cases of patients with NSCLC were randomly divided into two groups：group A （32 cases） undergoing chemotherapy after surgical treatment,and group B （29 cases） receiving chemotherapy after microwave ablation combined with ^131I-chTNT radioimmunotherapy.The clinical efficacy of two groups was compared,and the evaluation of quality of life was conducted.Results Six months after treatment,the local control rate of group A was 84.4%,and 89.7% in group B （P 〈 0.05）,but the adverse reactions in two groups was not statistically significant （P 〉0.05）.Quality of life scores after treatment were superior to those before treatment in group A and B,and significant differences were found in cognitive,emotional,social function scale,pain and dyspnea symptom scale scores between the two groups （all P 〈 0.05）.Conclusion ^131I-chTNT radioimmunotherapy combined with microwave ablation in treating NSCLC is safe and effective,which can significantly improve the quality of life in patients.

关 键 词：肺肿瘤 非小细胞肺癌 微波消融术 放射免疫治疗 ^131I-肿瘤细胞核人鼠嵌合单克隆抗体 生存质量 

分 类 号：R734.2[医药卫生—肿瘤]